comparemela.com

Latest Breaking News On - Sagar nigwekar - Page 1 : comparemela.com

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –– Phase 1 tr.

Massachusetts
United-states
Boston
American
Douglasa-treco
Stefan-riley
Christine-obrien
Inozyme-pharma
Matt-pera
Sagar-nigwekar
European-calcified-tissue-society-congress
Corporate-communications

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 - Inozyme Pharma (NASDAQ:INZY)

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

Boston
Massachusetts
United-states
Philadelphia
Pennsylvania
American
Inozyme-pharma
Sagar-nigwekar
Stefan-riley
Matt-pera
Research-advances-in-bone
Drug-administration

vimarsana © 2020. All Rights Reserved.